We warn of Palantir's overvaluation, insider selling, and limited growth prospects, advising caution to investors. Read more ...
On top of this, Bank of America recently added Palantir to its list of top investments and predicts the shares could rise 35% from their current level. The bank selected the stock for its U.S. 1 List ...
Zimmer Biomet's struggle with market share, operational improvements, and financial performance, with potential for growth.